Skip to main content

Hydrochlorothiazide / Moexipril Dosage

Applies to the following strengths: 12.5 mg-7.5 mg; 12.5 mg-15 mg; 25 mg-15 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Hypertension

Hydrochlorothiazide 12.5 to 25 mg-Moexipril 7.5 to 15 mg orally once a day 1 hour before a meal


  • If blood pressure is adequately controlled with hydrochlorothiazide 25 mg once a day monotherapy, but significant potassium loss occurs, blood pressure control without electrolyte disturbance may be achieved with hydrochlorothiazide 6.25 mg-moexipril 3.75 mg (one-half of a hydrochlorothiazide 12.5-moexipril 7.5 mg tablet).
  • May increase hydrochlorothiazide dose after 2 to 3 weeks at a given dose.
  • Total daily doses greater than hydrochlorothiazide 50 mg-moexipril 30 mg have not been studied in hypertensive patients.

Use: Treatment of hypertension not adequately controlled with monotherapy.

Renal Dose Adjustments

CrCl greater than 40 mL/min/1.73 m2: No adjustment recommended
CrCl 40 mL/min/1.73 m2 or less: Not recommended

Liver Dose Adjustments

Use with caution



  • FETAL TOXICITY: If pregnancy is detected, discontinue this drug as soon as possible. Drugs that act directly on the renin-angiotensin system (RAS) can cause injury and death to the developing fetus.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments


  • Monitor serum electrolytes prior to starting treatment and periodically thereafter.
  • Monitor renal function during the first few weeks of therapy.
  • Consider monitoring white blood cell counts in patients with collagen vascular disease, especially if the disease is associated with impaired renal function.

Patient advice:
  • Advise patients to take this drug 1 hour before a meal.
  • Advise patients to immediately report any signs or symptoms of angioedema (breathing difficulty or swelling of face, eyes, lips, or tongue) and to stop taking this drug until consulting a physician.
  • Encourage patients to report any lightheadedness that may occur during treatment initiation and to stop taking this drug until consulting a physician.
  • Caution patients to consult their physician if excessive perspiration, dehydration, vomiting, or diarrhea occurs as it may lead to excessive blood pressure reduction due to reduced fluid volume.
  • Advise patients against using potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes without consulting their physician.
  • Tell patients to promptly report any sign of infection (e.g., sore throat, fever), which may be a sign of neutropenia.
  • Females of childbearing age should be informed of the consequences of exposure to this drug during pregnancy; ask these patients to report pregnancies as soon as possible.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.